ArticleEuropean journal of nuclear medicine and molecular imaging2011
Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- [European journal of nuclear medicine and molecular imaging · 2020Article
- In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis.Heart (British Cardiac Society) · 2019Article
- Preparation and evaluation of aAmerican journal of nuclear medicine and molecular imaging · 2018Article
- Cardiac αHeart (British Cardiac Society) · 2017Article
- Preclinical validations of [EJNMMI radiopharmacy and chemistry · 2017Article
- Spectral Analysis of Dynamic PET Studies: A Review of 20 Years of Method Developments and Applications.Computational and mathematical methods in medicine · 2016Review
- Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3.Theranostics · 2016Review
- A novel PET tracer for targeted imaging of atherosclerosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Article
- Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.Physics in medicine and biology · 2015Review
- Radiopharmaceuticals as probes to characterize tumour tissue.European journal of nuclear medicine and molecular imaging · 2015Review
- Principles in the design of ligand-targeted cancer therapeutics and imaging agents.Nature reviews. Drug discovery · 2015Review
- Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.EJNMMI research · 2014Article
- [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.European journal of nuclear medicine and molecular imaging · 2014Article
- Radiolabeled RGD tracer kinetics annotates differential αvβ 3 integrin expression linked to cell intrinsic and vessel expression.Molecular imaging and biology · 2014Article
- Molecular imaging agents for SPECT (and SPECT/CT).European journal of nuclear medicine and molecular imaging · 2014Review
- Tumor quantification in clinical positron emission tomography.Theranostics · 2013Review
- Introduction to the analysis of PET data in oncology.Journal of pharmacokinetics and pharmacodynamics · 2013Review
- Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model.Molecular imaging and biology · 2012Article
- PET Tracers for Clinical Imaging of Breast Cancer.Journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe purpose of the study was to estimate the receptor-ligand binding of an arginine-glycine-aspartic acid (RGD) peptide in somatic tumours. To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the α(v)β(3/5) integrin receptor radioligand [(18)F]fluciclatide.
methodsFirst, compartmental modelling and spectral analysis with arterial input function were performed at the region of interest (ROI) level in healthy lung and liver, and in lung and liver metastases; compartmental modelling was also carried out at the pixel level. The selection of the most appropriate indexes for tumour/healthy tissue differentiation and for estimation of specific binding was then assessed.
resultsThe two-tissue reversible model emerged as the best according to the Akaike Information Criterion. Spectral analysis confirmed the reversibility of tracer kinetics. Values of kinetic parameters, estimated as mean from parametric maps, correlated well with those computed from ROI analysis. The volume of distribution V(T) was on average higher in lung metastases than in the healthy lung, but lower in liver metastases than in the healthy liver. In agreement with the expected higher α(v)β(3/5) expression in pathology, k(3) and k(3)/k(4) were both remarkably higher in metastases, which makes them more suitable than V(T) for tumour/healthy tissue differentiation. The ratio k(3)/k(4), in particular, appeared a reasonable measure of specific binding.
conclusionBesides establishing the best quantitative approaches for the analysis of [(18)F]fluciclatide data, this study indicated that the k(3)/k(4) ratio is a reasonable measure of specific binding, suggesting that this index can be used to estimate α(v)β(3/5) receptor expression in oncology, although further studies are necessary to validate this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.